Interim Results 2018/19 Martin Morgan, Executive Chairman Richard Amos, Chief Financial Officer London, 21 February 2019
Safe Harbour Statement This presentation and the subsequent question and answer session may contain forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. There are risk factors that could cause results to differ materially from those expressedor implied by such statements. Wilmington disclaims any intention or obligation to revise or update any forwardlooking statements that may be made during this presentation or the subsequent question and answer session, regardless of whether those statements are affected as a results of new information, future events or otherwise.
Agenda Introduction and highlights Martin Morgan Operational review and financial highlights Richard Amos Strategy update Martin Morgan Q & A Martin Morgan/ Richard Amos 2
Introduction and highlights 3
Highlights Progress in H1 rebuilding growth trajectory Good growth in Risk & Compliance division Professional division stable in period Improvement in Healthcare performance with UK sales up healthily year-on-year Cash generation strong Cash conversion strong at 91% (31 Dec 2017: 77%) Net debt at period end 43.8m (31 Dec 2017: 45.9m) Outflow in half reflects seasonal H1 payments Revenue of 58.3m flat on H1 last year Organic growth also flat Compares to 3% organic decline last year in H1 and FY A shift in momentum Progressive dividend policy maintained Interim dividend increased 3% to 4.1p (2017: 4.0p) To be paid 8 April (ex-div 7 March) Adjusted* PBT reduced to 6.7m (2017: 9.1m) Reduction driven by anticipated cost increases New office Inflation New product investment Business review completed Positive conclusions to be drawn Confirms organic growth opportunity Need to accelerate the pace of change *Adjusted results exclude adjusting items, profit on disposal of property plant and equipment, gain on sale of subsidiary, impairment of goodwill and intangible assets and amortisation of intangible assets (excluding computer software). ** Organic = at constant currency and excluding impact of acquisitions and disposals 4
Operational review 5
Risk & Compliance 6 mths to 31 Dec Revenue Operating Profit Margin % 2018 m Revenue by Region 2017 m 20.1 19.6 5.9 5.4 29% 27% Absolute Variance % 3% 10% Organic Variance % 8% 23% Revenue by Type 20% organic revenue growth in main Compliance business some growth timing related strong demand for in-house courses in Europe ICA membership up 2,000 to over 14,000 Online learning up 45% year on year Other Compliance businesses flat revenue Compliance Week moving to new platform in H2 New online courses launched for wealth management area New MD appointed to run wealth management Risk businesses flat revenue overall ICP sold at start of year impacts absolute variances Axco growth in H1 under new management team InsurTech JV launched in period first sales achieved Inese weak demand for training courses 6
Healthcare 6 mths to 31 Dec Revenue Operating Profit Margin % 2018 m Revenue by Region 2017 m 20.5 20.8 1.3 3.7 6% 18% Absolute Variance % (1%) (66%) Organic Variance % (5%) (57%) Revenue by Type Progress in European Healthcare Revenue decreased 2% organically versus an 8% reduction last year European Healthcare businesses reporting directly to Executive Chairman French business good growth including launch of APMi service UK business new sales bookings up materially on H1 last year helps revenue growth in H2 New versions of Quantis and Investigator products launched in period IM platform integrated into data solutions Consulting offering gaining traction with new clients US Healthcare traditionally quiet first half Revenue down due mainly to programme rationalisation Extra sales resource hired to action leads RISE Nashville sales looking promising Profit impacted by infrastructure investments, APMi costs and IM acquisition 7
Professional 6 mths to 31 Dec Revenue Operating Profit Margin % 2018 m Revenue by Region 2017 m 17.7 17.9 2.9 3.2 17% 18% Absolute Variance % (1%) (9%) Organic Variance % (2%) (8%) Revenue by Type Accountancy slow start to year Impacted by Brexit hiatus Integration of brands completed New CRM platform adoption in progress - due live by 30 June Prepared for H2 Brexit related opportunities once outcome is known Legal good H1 Good growth driven by Bond Solon Success with Witness Familiarisation and new areas including employment law Framework contract won with major Government agency Law for Lawyers online courses launched Investment Banking making progress New MD in place Good peak summer training season New online learning platform being launched for summer 2019 Overall digital training now c.30% of total group training revenue 8
Financial highlights 9
Revenue by division Revenue 6 mths to 31 Dec 2018 6 mths to 31 Dec 2017* Absolute variance Organic variance m m % % Compliance 13.8 12.1 14% 13% Risk 6.3 7.5 (16%) - Total Risk & Compliance 20.1 19.6 3% 8% European Healthcare 14.6 14.2 3% (2%) US Healthcare 2.5 3.1 (19%) (21%) Other Information Businesses 3.4 3.5 (4%) (4%) Total Healthcare 20.5 20.8 (1%) (5%) Continuing businesses 17.7 17.7 - - Ark business closed - 0.2 Total Professional 17.7 17.9 (1%) (2%) Total Group Revenue 58.3 58.3 +0.0% +0.5% Absolute variance in Risk reflects disposal of ICP business European Healthcare absolute variance impacted by acquisition of IM last H2. US Healthcare organic reduction includes rationalisation of event programme conducted last year Healthcare 5% organic revenue reduction versus an 8% reduction last year * 2017 comparatives restated to reflect adoption of IFRS 15 and to reallocate US events revenue from Professional to Healthcare see page 32 for detail. 10
Revenue bridge m 11
Adjusted EBITA bridge m 12
Income statement 6 months 6 months to to Dec 2018 Dec 2017 Restated Variance Absolute variance Organic variance m m m % % Revenue 58.3 58.3 - - - Adjusted EBITA 7.8 10.1 (2.3) (23%) (13%) EBITA margin 13% 17% Finance costs (1.0) (1.0) Share of profit of JV (0.1) - Adjusted profit before tax 6.7 9.1 (2.4) (26%) Adjusting items (0.1) (3.5) 3.4 Gain on sale of ICP 1.9-1.9 Amortisation of acquired intangible assets (2.6) (3.4) 0.8 Statutory profit before tax 5.8 2.2 3.6 Taxation (0.8) (0.8) - Statutory profit after tax 5.0 1.4 3.6 Underlying tax rate 20% 22% Adjusted basic EPS 6.16p 8.08p (24%) Dividend per share 4.1p 4.0p 3% 13
Cash flow 6 months to 6 months to Dec 2018 Dec 2017 Restated Variance m m m % Adjusted EBITDA 9.0 11.1 (2.1) (19%) SBP - 0.3 (0.3) Movement in WC (1.9) (3.7) 1.8 Cash inflow from operations 7.1 7.7 (0.6) (8%) Interest paid (1.0) (1.0) - Tax paid (2.3) (2.5) 0.2 Net capital expenditure (1.3) (3.9) 2.6 Free cash flow before dividends 2.5 0.3 2.2 733% Equity dividends (4.2) (4.1) (0.1) Cash on SBP - (0.1) 0.1 Acquisition spend (0.1) - (0.1) Deferred consideration (1.5) (0.5) (1.0) Disposal of subsidiary 0.1-0.1 Adjusting and other items (0.5) (2.0) 1.5 Change in net debt during the year (3.7) (6.4) 2.7 (42%) Cash conversion strong at 91% versus 77% last year Led by improved working capital management Capex returned to normal levels after one-offs from last year 2.5-3.0m guidance for full year still remains Deferred consideration primarily reflects SWAT payment Brought forward net debt (39.6) (40.0) 0.4 FX (0.5) 0.5 (1.0) Carried forward net debt (43.8) (45.9) 2.1 (5%) 14
Summary balance sheet 31 Dec 31 Dec 2017 2018 Restated m m Fixed assets Goodwill/intangibles 102.6 113.3 Property and P&E 6.4 6.4 Other fixed assets 0.8 1.2 Working capital Deferred revenue (26.6) (27.6) Other working capital 2.7 3.4 Cash/Debt Net debt (43.8) (45.9) Capitalised bank fees 0.2 0.4 Deferred consideration payable (1.3) (2.4) Deferred consideration receivable 2.2 - Financial instruments (0.5) (0.5) Other Tax assets/(liabilities) 0.5 (0.7) Deferred tax (2.8) (3.2) Net Assets 40.4 44.4 IFRS 15 changes 1.5m netting off debtors and deferred revenue 2.8m opening adjustment to deferred revenue offset by opening reserves 0.4m deferred tax benefit which will flow through over the next 18 months Deferred revenue excludes 2m of confirmed orders still to be invoiced at 31 December 2018 Debt at 43.8m represents 58% of available facility (Dec 2017: 61%) IFRS 16 comes into force from 1 July 2019 Guidance on impact will be given at Prelims 15
Current trading and outlook Outlook in line with September guidance Second half weighting expected to continue this year Risk & Compliance continued growth from H1 Healthcare sales performance to drive expected H2 revenue uplift Professional stable with opportunity for H2 growth once Brexit path known Costs in line with previous guidance other than 0.5m extra for CEO departure/replacement - this will be treated as an adjusting item New product development funded through existing capex guidance On-track to achieve full year expectations 16
Strategy update 17
Business review - analysis The review reached generally positive conclusions: Core businesses operating in healthy markets with growth prospects - others generally in stable markets We have a portfolio of well recognised and respected brands with leading market shares Pace of market change is fast but no imminent material threat from disruptors, but we do operate in competitive markets Opportunities to evolve business models Decision to focus on organic growth and deprioritise acquisitions validated Shift in focus away from building a pan-european healthcare information business, concentrating on strong existing positions in UK and France 18
Business review - implementation New CEO to focus on refinement and implementation of the strategy, not on another strategic review New 3 year planning exercise to create detailed plans, including identifying investment opportunities Complete roll-out of software platforms in digital learning, marketing and customer relationship management Work on improving sales and marketing execution, including a review of pricing models Sustain cross-group sharing of expertise, e.g. in digital learning Build further on senior management incentive changes to align with organic growth objective Streamline organisation to ensure the major growth opportunities are effectively grasped 19
Review of business: UK Accountancy Brand Proposition Education, marketing and compliance services to SME accountancy practices in the UK and Ireland Market Opportunity Stable market conditions growth 0-3% Brand Position Growth Opportunity Number one player, further strengthened with acquisition of strong regional provider (previous number two) Leverage leading position by cross-selling existing and new digital value-add products 20
Review of business: European Healthcare Brand Proposition Intelligence on UK and French healthcare markets and providing decision-makers to suppliers into those markets Market Opportunity Brand Position Changing demographics and positive growth trends in NHS and French Healthcare Service spending growth c.5% One of top 3 UK players; niche player in France Growth Opportunity Build on existing components of the business to become the leading information gateway to the UK and French Healthcare markets 21
Review of business: Global Compliance Brand Proposition Education, events and insights to enable financial institutions to manage compliance Market Opportunity Brand Position Growth Opportunity Growing international regulatory environment growth 5%+ Leading player in Europe, Middle East and other parts of Asia Evolve the business model at an enterprise level, coupled with geographic expansion 22
Summary Summary Entering key period in the second half of the year Business review has confirmed strategy and priorities Opportunities for growth and performance improvements identified On track to meet full year expectations 23
Q&A 24
Appendices 25
Glossary APMi CRM New product being developed by APM International, French based healthcare company Customer relationship management software ICA International Compliance Association Wilmington owned compliance industry body ICP International Company Profile credit referencing business sold in July 2018 IM Interactive Medica Acquired Feb 2018 Investigator Most granular online library of UK healthcare data which includes over 450,000 healthcare personnel Quantis A platform, both online and offline to display UK healthcare data WHC Wilmington Healthcare Limited 26
27 Financial progress overview Revenue up (% of Group Revenue) EBITA anticipated reduction (% of Group EBITA) Overall margins Reported Growth Reported Growth EBITA Margin Dec 2018 EBITA Margin Dec 2017 Risk & Compliance 35% +3% Risk & Compliance 58% +10% 29% 27% Professional 30% (1%) 17% 18% Healthcare 35% (1%) Professional Healthcare 29% 13% (9%) (66%) 6% 18% Revenue 58.3m 0% EBITA EBITA 7.8m (23%) Wilmington plc (adjusted EBITA margin) 13% 17%
28 Profile of the business Turning knowledge to advantage REVENUE BY AREAS OF KNOWLEDGE REVENUE BY REGIONS REVENUE BY TYPE NETWORKING 9% (12%) PROFESSIONAL 30% (30%) HEALTHCARE 35% (36%) RISK & COMPLIANCE 35% (34%) NORTH AMERICA 15% (16%) 19% ROW 8% (9%) EUROPE (16%) UK 58% (59%) INFORMATION 50% (50%) TRAINING 41% (38%) ( ) Dec 2017 figures
Adjusted EBITA by division 6 months to Dec 18 6 months to Dec 17 Absolute Organic Restated variance variance m m % % Adjusted EBITA Risk & Compliance 5.9 5.4 10% 23% Healthcare 1.3 3.7 (66%) (57%) Professional 2.9 3.2 (9%) (7%) Group overheads (2.3) (1.9) Share based payments - (0.3) Total 7.8 10.1 (23%) (13%) 29
IFRS 15 balance sheet at 31 December 2017 restatement Previously reported IFRS 15 adjustment revenue recognition IFRS 15 adjustment net down of balance sheet Restated 000 000 000 000 Non current assets: Deferred tax assets 590 366-956 Other non-current assets 119,817 - - 119,817 Current assets: Trade and other receivables 28,233 - (1,483) 26,750 Other current assets 12,143 - - 12,143 Total assets 160,783 366 (1,483) 159,666 Current liabilities: Trade and Other Payables (23,270) - - (23,270) Current liabilities: Deferred revenue (26,342) (2,768) 1,483 (27,627) Other current liabilities (3,888) - - (3,888) Other non-current liabilities (60,518) - - (60,518) Total liabilities (114,018) (2,768) 1,483 (115,303) Net assets 46,765 (2,402) - 44,363 30
IFRS 15 balance sheet at 30 June 2018 restatement Previously reported IFRS 15 adjustment revenue recognition Restated 000 000 000 Non current assets: Deferred tax assets 458 479 937 Other non-current assets 110,984-110,984 Current assets: Trade and other receivables 28,233-28,233 Other current assets 11,106-11,106 Total assets 150,781 479 151,260 Current liabilities: Trade and Other Payables (26,368) - (26,368) Current liabilities: Deferred revenue (24,746) (3,365) (28,111) Other current liabilities (2,042) - (2,042) Other non-current liabilities (55,109) - (55,109) Total liabilities (108,265) (3,365) (111,630) Net assets 42,516 (2,886) 39,630 31
Reconciliation of FY2018 P&L restatement Half Year to 31 Dec 2017 Full Year to 30 June 2018 Revenue Dec 2017 Reported Segmental Restatement IFRS 15 Restatement Dec 2017 Restated Jun 2018 Reported IFRS 15 Restatement Jun 2018 Restated Risk & Compliance 19,596 (147) 97 19,546 42,860 (539) 42,321 Healthcare 20,083 748-20,831 44,681-44,681 Professional 18,480 (601) 23 17,902 34,551 61 34,612 Revenue 58,159-120 58,279 122,092 (478) 121,614 Adjusted EBITA Risk & Compliance 5,249 9 97 5,355 12,899 (538) 12,361 Healthcare 3,921 (203) - 3,718 9,899-9,899 Professional 2,986 194 23 3,203 6,230 60 6,290 12,156-120 12,276 29,028 (478) 28,550 Unallocated Central Overheads (1,860) - - (1,860) (3,827) - (3,827) Share Based Payments (338) - - (338) (641) - (641) Adjusted EBITA 9,958-120 10,078 24,560 (478) 24,082 32
Thank you. 33